Analyst Reco. Alnylam Pharmaceuticals, Inc.

Stocks

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:02:27 2026-06-10 pm EDT			5-day change	1st Jan Change
295.72 ^USD	-0.66%		+1.35%	-25.43%

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Analyst Reco.

May. 01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
Feb. 13	RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating	MT
Jan. 20	RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating	MT
25-10-27	Intellia pauses gene therapy trials after patient suffers liver injury, shares slide	RE
25-10-06	Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating	MT
25-09-19	RBC Raises Price Target on Alnylam Pharmaceuticals to $500 From $435, Keeps Outperform Rating	MT
25-08-04	Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says	MT
25-08-04	Wolfe Upgrades Alnylam Pharmaceuticals to Peer Perform From Underperform	MT
25-08-04	Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform From Market Perform, Price Target is $490	MT
25-08-01	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $550 From $403, Maintains Buy Rating	MT
25-07-21	Truist Securities Initiates Coverage on Alnylam Pharmaceuticals With Buy Rating, $385 Price Target	MT
25-07-07	RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	MT
25-05-02	UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	MT
25-04-17	BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	MT
25-03-24	JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280	MT
25-03-21	BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating	MT
25-03-21	RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating	MT
25-02-14	RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating	MT
24-12-02	Mirae Asset Downgrades Alnylam Pharmaceuticals to Hold, Price Target is $236	MT
24-11-12	Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade	MT
24-11-12	Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205	MT
24-10-16	Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target	MT
24-09-20	China Merchants Initiates Alnylam Pharmaceuticals at Buy With $360 Price Target	MT
24-09-19	Alnylam Pharma Confident in ATTR-CM Treatment's Market Potential, Cautious on Regulatory Risks, RBC Says	MT
24-08-19	UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained	MT